GlassScriptPhysician profile
Jonathan T Miller
NPI 1619172285
$10,232.66
in general payments reported to CMS, 2019-2025
49 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $1,456 · 2021: $1,843 · 2022: $1,434 · 2023: $1,420 · 2024: $1,355 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,993.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,703.32 | 2021-2025 | |
| Novo Nordisk INC | $1,587.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $785.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $739.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $587.90 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $530.15 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.83 | 2019-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $455.15 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $416.95 | 2019-2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $350.21 | 2019-2025 | |
| Amgen INC. | $345.70 | 2019-2025 | Evenity, Prolia, Prolia |
| Allergan, INC. | $272.87 | 2019-2020 | |
| Lilly USA, LLC | $253.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $238.60 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $233.59 | 2019-2023 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $188.11 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $95.19 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $89.20 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $74.43 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $64.12 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $57.71 | 2024-2025 | Voquezna |
| Eisai INC. | $51.27 | 2020-2022 | |
| Corcept Therapeutics | $50.92 | 2022-2025 | Korlym |
| Hikma Pharmaceuticals USA | $49.98 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $42.56 | 2019-2021 | |
| Seqirus USA INC | $41.50 | 2022-2025 | Flucelvax |
| Daiichi Sankyo INC. | $36.36 | 2019-2021 | |
| Sanofi Pasteur INC. | $31.59 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.67 | 2019-2020 | |
| Lundbeck LLC | $26.22 | 2023 | Vyepti |
| Viatris Specialty LLC | $23.51 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $22.93 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.14 | 2023 | Rexulti |
| Sk Life Science, INC. | $20.86 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.64 | 2021 | |
| Eyevance Pharmaceuticals LLC | $19.19 | 2021 | |
| Ardelyx, INC. | $18.67 | 2025 | Ibsrela |
| Paratek Pharmaceuticals, INC. | $18.47 | 2025 | Nuzyra |
| Shield Therapeutics INC | $18.14 | 2023 | Accrufer |
| Mylan Specialty L.P. | $16.92 | 2020 | |
| Mallinckrodt Hospital Products INC. | $16.27 | 2022 | |
| Almatica Pharma LLC | $15.63 | 2023 | Loreev Xr |
| Genentech USA, INC. | $14.84 | 2019 | |
| Horizon Therapeutics Plc | $14.81 | 2023 | Tepezza |
| Idorsia Pharmaceuticals US INC | $13.75 | 2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $13.09 | 2019 | |
| Antares Pharma, INC. | $12.28 | 2020 | |
| Melinta Therapeutics, LLC | $11.84 | 2019 | |
| Endo Pharmaceuticals INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.